Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

209 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Drug discovery targeting the chemokine system--where are we?
Horuk R, Proudfoot AE. Horuk R, et al. Front Biosci (Elite Ed). 2009 Jun 1;1:209-19. Front Biosci (Elite Ed). 2009. PMID: 19482638 Review.
Strategies for chemokine antagonists as therapeutics.
Proudfoot AE, Power CA, Rommel C, Wells TN. Proudfoot AE, et al. Semin Immunol. 2003 Feb;15(1):57-65. doi: 10.1016/s1044-5323(02)00128-8. Semin Immunol. 2003. PMID: 12495641 Review.
Targeting chemokines: Pathogens can, why can't we?
Proudfoot AE, Bonvin P, Power CA. Proudfoot AE, et al. Cytokine. 2015 Aug;74(2):259-67. doi: 10.1016/j.cyto.2015.02.011. Epub 2015 Mar 6. Cytokine. 2015. PMID: 25753743 Review.
Current status of chemokine receptor inhibitors in development.
Allegretti M, Cesta MC, Garin A, Proudfoot AE. Allegretti M, et al. Immunol Lett. 2012 Jul 30;145(1-2):68-78. doi: 10.1016/j.imlet.2012.04.003. Epub 2012 Apr 20. Immunol Lett. 2012. PMID: 22698186 Review.
Anti-chemokine small molecule drugs: a promising future?
Proudfoot AE, Power CA, Schwarz MK. Proudfoot AE, et al. Expert Opin Investig Drugs. 2010 Mar;19(3):345-55. doi: 10.1517/13543780903535867. Expert Opin Investig Drugs. 2010. PMID: 20113217 Review.
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. Bachelerie F, et al. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Pharmacol Rev. 2013. PMID: 24218476 Free PMC article. Review.
Chemokine cooperativity is caused by competitive glycosaminoglycan binding.
Verkaar F, van Offenbeek J, van der Lee MMC, van Lith LHCJ, Watts AO, Rops ALWMM, Aguilar DC, Ziarek JJ, van der Vlag J, Handel TM, Volkman BF, Proudfoot AEI, Vischer HF, Zaman GJR, Smit MJ. Verkaar F, et al. J Immunol. 2014 Apr 15;192(8):3908-3914. doi: 10.4049/jimmunol.1302159. Epub 2014 Mar 17. J Immunol. 2014. PMID: 24639348 Free PMC article.
Overcoming hurdles in developing successful drugs targeting chemokine receptors.
Schall TJ, Proudfoot AE. Schall TJ, et al. Nat Rev Immunol. 2011 May;11(5):355-63. doi: 10.1038/nri2972. Epub 2011 Apr 15. Nat Rev Immunol. 2011. PMID: 21494268 Review.
The use of chemokine antagonists in EAE models.
Proudfoot AE, de Souza AL, Muzio V. Proudfoot AE, et al. J Neuroimmunol. 2008 Jul 31;198(1-2):27-30. doi: 10.1016/j.jneuroim.2008.04.007. Epub 2008 Jun 11. J Neuroimmunol. 2008. PMID: 18550179 Review.
Chemokine blockers--therapeutics in the making?
Wells TN, Power CA, Shaw JP, Proudfoot AE. Wells TN, et al. Trends Pharmacol Sci. 2006 Jan;27(1):41-7. doi: 10.1016/j.tips.2005.11.001. Epub 2005 Nov 28. Trends Pharmacol Sci. 2006. PMID: 16310864 Review.
209 results
Jump to page
Feedback